Shares of Faron Pharmaceuticals Oy (LON:FARN - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as GBX 252 ($3.35) and last traded at GBX 250 ($3.32), with a volume of 45377 shares trading hands. The stock had previously closed at GBX 239 ($3.18).
Faron Pharmaceuticals Oy Stock Performance
The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The stock has a fifty day moving average price of GBX 191.56 and a 200-day moving average price of GBX 185.89. The firm has a market cap of £285.15 million, a price-to-earnings ratio of -5.68 and a beta of 0.36.
Faron Pharmaceuticals Oy Company Profile
(
Get Free Report)
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
Before you consider Faron Pharmaceuticals Oy, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Faron Pharmaceuticals Oy wasn't on the list.
While Faron Pharmaceuticals Oy currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
